This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April

This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing.
Open original source
This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing.
Open original source